The Fasting Question: What GLP-1 Microdosing Means Before Surgery, Endoscopy, and Anesthesia
Every preoperative fasting rule ever written assumes a stomach that empties on schedule. These medications are designed to break that assumption.
~1 WEEK
SEMAGLUTIDE HALF-LIFE, WHICH MEANS A SEVEN-DAY HOLD REMOVES ABOUT HALF THE DRUG
4–6×
TYPICAL PUBLISHED ODDS RATIO FOR RETAINED GASTRIC CONTENT AT UPPER ENDOSCOPY
24 HOURS
CLEAR LIQUID DIET AT THE CENTER OF THE 2024 MULTISOCIETY GUIDANCE
Nothing after midnight. That instruction is roughly a century old, and it survives because it usually works. A healthy stomach clears a light meal in about six hours and clear liquids in about two, so a fast that runs from evening to morning leaves an anesthesiologist with an empty organ and a protected airway.
GLP-1 receptor agonists interfere with that arithmetic on purpose. Slowed gastric emptying is not a side effect of these medications, it is a substantial part of how they blunt appetite. When someone taking one arrives for a colonoscopy or a knee replacement, the fasting interval on the chart no longer describes what is inside the stomach. Anesthesiology noticed, published a blanket holding rule in 2023, then revised the whole approach in 2024 after the data came in. This article covers what endoscopy actually found, why the one-week hold clears far less drug than most people assume, how dose size and treatment duration change the picture, and what a person on a low-dose protocol should say when a procedure gets booked.
Key takeaways
- •Endoscopy studies have found retained gastric content after an adequate fast in roughly a quarter of GLP-1 users versus a low single-digit percentage of non-users, with published odds ratios commonly between four and six.
- •Semaglutide has a half-life near one week, so the widely repeated seven-day hold leaves approximately 50 percent of the drug in circulation rather than clearing it.
- •The 2023 American Society of Anesthesiologists statement recommended holding weekly agents for one week; the 2024 multisociety guidance replaced that blanket rule with risk stratification and a 24-hour clear liquid diet for most patients.
- •Gastric emptying delay is dose-dependent and attenuates over months of continued exposure, which places the escalation phase at higher risk than a long-stable maintenance dose.
- •Active nausea, vomiting, or a sense of food sitting after meals is the strongest single predictor of residual gastric content, and it outweighs dose in most risk assessments.
- •Point-of-care gastric ultrasound can assess residual stomach contents directly on the day of the procedure, which answers the question rather than inferring it from a hold interval.
How often is food still in the stomach after a proper fast?
Roughly a quarter of the time in GLP-1 users, against a low single-digit percentage in matched patients who are not taking one. Upper endoscopy is the reason this question has a real answer rather than an estimate. The operator passes a camera into a stomach that, according to the fasting instructions on the chart, should be empty, and simply records what is there. Several retrospective series published from 2023 onward converged on the same finding, and pooled analyses have reported odds ratios for retained content commonly in the range of four to six.
The distribution inside that average matters more than the average itself. Retained content clusters heavily among patients reporting gastrointestinal symptoms in the weeks before the procedure, and among those still moving up through dose escalation. Patients who had been on a stable dose for months without symptoms looked considerably closer to the non-user group, though not identical to it. Most of these series enrolled patients on standard therapeutic doses prescribed for diabetes or weight management, which is a real limitation when applying the numbers to a low-dose protocol.
Retained gastric content at upper endoscopy after an adequate fast
Approximate percentages synthesized from published retrospective endoscopy series and pooled analyses. Study definitions of residual content and fasting protocols varied, so these values illustrate the gradient rather than any single trial result.
Does holding the dose for a week actually clear the drug?
It clears about half of it. Semaglutide has an elimination half-life of approximately one week, which is the property that makes weekly injection possible in the first place. Seven days after the last dose, roughly 50 percent of the circulating drug remains. Tirzepatide, with a half-life closer to five days, drops to somewhere near a third over the same window. Reaching negligible concentrations requires four to five half-lives, meaning four to five weeks for semaglutide.
This is the arithmetic that undermined the original blanket rule. A one-week hold was never a washout, and it was never presented as one by the people who wrote it, but it was widely received as though a held dose meant a cleared drug. Meanwhile the hold has costs that fall on the patient rather than on the schedule: interrupted glycemic control in people with diabetes, a rebound in appetite, and for anyone on a carefully titrated protocol, the loss of a stable position that took months to reach. When a rule imposes real cost and removes half a problem, it invites the sort of reassessment that arrived in 2024.
Remaining drug concentration after the final dose
Modelled single-compartment decay from published half-life values, approximately 7 days for semaglutide and 5 days for tirzepatide, with the last dose set to 100. Illustrative pharmacokinetics rather than measured patient concentrations.
- Semaglutide
- Tirzepatide
Does a smaller dose slow the stomach less?
Yes, and the relationship is one of the better characterized in the class. Pharmacology studies measuring gastric emptying across the semaglutide dose range show a graded effect, with the starting dose producing modest slowing and the maximum weight management dose producing several times more. The receptor-level explanation is unremarkable: more occupancy produces more vagal signalling to the stomach, and the response scales rather than switching on at a threshold.
What follows from that gradient is narrower than people usually want it to be. A protocol running at a fraction of a therapeutic dose is producing less delay than one titrated to 2.4 mg, which is a mechanistic argument worth understanding. It is not a safety clearance, because no study has compared microdose protocols against full-dose protocols for residual gastric content, and no dose has been identified below which the fasting question stops applying. The correct use of the dose gradient is as information for the anesthesia team, not as a reason to skip telling them.
Relative gastric emptying delay by semaglutide dose
Illustrative index of solid-phase emptying delay across the dose range, scaled to a common baseline. Conceptual representation of the dose-response pattern described in pharmacology studies rather than measured emptying times.
Why does the escalation phase carry more risk than maintenance?
Because the effect on gastric emptying fades with continued exposure while the appetite effect largely does not. This attenuation has been documented across the GLP-1 class, including in crossover work with semaglutide where the delay measured in the first weeks of treatment was markedly reduced by around week twelve. The stomach adapts to a steady signal in a way the appetite circuitry does not, which is a genuinely useful asymmetry and also the reason nausea tends to be worst right after a dose increase.
For procedural planning, that turns a single question into two. Someone who has been at the same dose for eight months without symptoms sits in a different position from someone who stepped up a level nine days ago, even if the number on the pen is identical. The 2024 guidance reflects this directly by treating escalation as a risk factor in its own right. It is also an argument for planning elective procedures during a stable stretch rather than in the middle of a titration, which is one of the few pieces of this that a patient can control in advance.
Attenuation of gastric emptying delay over treatment duration
Delay indexed to 100 at week one of a stable dose. Conceptual model of the tachyphylaxis pattern reported in gastric emptying studies of GLP-1 receptor agonists, not individual measurements.
- Emptying delay index
How did the preoperative guidance change between 2023 and 2024?
It moved from one rule applied to everyone to a risk assessment applied to each patient. The 2023 American Society of Anesthesiologists consensus statement was written quickly, in response to case reports of aspiration and regurgitation in GLP-1 users, and it said what a first response usually says: hold weekly agents for a week, hold daily agents on the day. That statement was explicitly consensus-based rather than evidence-based, and it acknowledged as much.
The 2024 multisociety clinical practice guidance, developed jointly by anesthesiology, gastroenterology, and bariatric surgery organizations, took a different shape once outcome data accumulated. Its central move was to stop treating GLP-1 use as a single category. Most patients continue the medication. Preparation shifts toward a 24-hour clear liquid diet, which addresses the actual mechanism, since these drugs delay solid emptying far more than liquid emptying. Risk stratification identifies who needs more caution, and point-of-care gastric ultrasound offers a way to assess the stomach directly when the answer is genuinely uncertain.
| Scenario | 2023 consensus approach | 2024 risk-stratified approach |
|---|---|---|
| Weekly injectable, currently escalating the dose | Hold the medication for one week before the procedure. | Treated as elevated risk. Clear liquid diet for 24 hours, gastric ultrasound if available, and a decision about holding made by the anesthesia team rather than a fixed rule. |
| Weekly injectable, stable low dose for several months, no symptoms | Hold the medication for one week before the procedure. | Generally continued. The 24-hour clear liquid diet does most of the work, and stopping a stable protocol carries its own metabolic cost. |
| Any dose with active nausea, vomiting, or early fullness | Hold, and consider delaying the procedure. | Highest risk category regardless of dose. Symptoms are treated as direct evidence of delayed emptying rather than as an inconvenience. |
| Daily formulation | Hold on the day of the procedure. | Same-day hold remains reasonable, with the rest of the assessment driven by symptoms and diet rather than the hold itself. |
| Emergency or unscheduled procedure | Not addressed by an elective holding rule. | Managed as a full stomach when GLP-1 use cannot be excluded, using rapid sequence induction and airway protection. |
| Uncertainty at the door on procedure day | Cancel and reschedule. | Point-of-care gastric ultrasound where an operator is available, since it answers the actual question instead of estimating it from a calendar. |
What makes one patient higher risk than another?
Symptoms outrank everything else. Ongoing nausea, vomiting, bloating, or the sensation of food sitting hours after a meal is not background discomfort in this context, it is direct evidence that the stomach is emptying slowly right now. A patient reporting those symptoms is treated as elevated risk regardless of dose, and that single input carries more weight in most published risk frameworks than the number of milligrams involved.
Below symptoms sit the structural factors. Active dose escalation ranks high because the stomach has not yet adapted. Maximum therapeutic dosing ranks high for the dose-response reason described earlier. Solid food eaten within 24 hours of the procedure matters because solids are precisely what these medications hold up. Pre-existing gastroparesis and long-standing diabetes with autonomic involvement add a second, independent source of delay. At the bottom sits the profile that describes many people on a maintenance protocol, which is a stable low dose held for months with no gastrointestinal symptoms at all.
Relative weight of factors in preoperative risk assessment
Qualitative ranking synthesized from published risk-stratification frameworks. Values express relative emphasis rather than measured probabilities, and no framework substitutes for an individual clinical assessment.
Why does a clear liquid diet do more than a longer fast?
Because liquids and solids leave the stomach by different mechanisms, and GLP-1 receptor agonists affect one far more than the other. Clear liquids drain largely by pressure gradient and pass through the pylorus without needing to be broken down. Solids must first be ground down by antral contractions into particles small enough to exit, and that grinding phase is exactly what these medications slow. Extending a fast on solid food adds hours to a process that has been made unpredictable, while removing solids entirely removes the variable.
This is why the 2024 guidance put a 24-hour clear liquid diet at the center of preparation instead of a longer overnight fast. Clear liquids in this sense means water, clear broth, pulp-free juice, plain tea, and black coffee without milk. Protein shakes, smoothies, and anything with milk or cream do not qualify, however liquid they look, because they behave like solids once they hit stomach acid. The specific instruction still has to come from the procedural team, since a colonoscopy prep and a general anesthetic have different requirements that override any general advice.
Relative residual gastric content by preparation strategy
Standard 8-hour solid fast indexed to 100. Illustrative comparison of preparation approaches based on the mechanism described in preoperative guidance, not pooled trial data.
Can anyone check whether the stomach is empty?
Point-of-care gastric ultrasound does exactly that, at the bedside, in a few minutes. The operator images the gastric antrum with the patient positioned on their right side and grades what is visible: an empty antrum, clear fluid only, or solid content. Anesthesiology has used the technique for years in obstetric and emergency settings where fasting status is unknown, and the 2024 guidance names it as a tool for GLP-1 users when risk assessment leaves genuine uncertainty on the day.
The limitation is availability rather than accuracy. Gastric ultrasound requires a trained operator and a free machine, and neither is universal outside larger centers. Where it exists, it converts an estimate into an observation, which is a meaningful upgrade over inferring stomach contents from a hold interval. Where it does not, the decision falls back to symptoms, diet, dose, escalation status, and the judgment of the anesthesia team, which is a reasonable position and also the reason the information a patient provides at booking carries so much weight.
"A hold interval estimates what is in the stomach. An ultrasound probe looks. Where the second option exists, the first stops being the deciding factor."
The honest version
The risk here is real, well documented, and almost entirely manageable with information given early. Delayed gastric emptying is a designed feature of these medications, and preoperative fasting rules were written for stomachs that do not have that feature. The failure mode is not a patient on a GLP-1 receptor agonist, it is an anesthesia team that finds out about one at the door.
The practical version fits in a sentence or two. Tell whoever books the procedure the drug name, the dose, the date of the last injection, how long you have been at that dose, and whether anything feels like it is sitting after meals. Schedule elective work during a stable stretch rather than mid-titration when there is a choice. Follow the preparation instruction the procedural team gives rather than a general rule read online, because they know what the procedure requires. Do not decide independently to hold or continue a dose, in either direction, since both choices carry consequences that belong to a clinician. A low dose is a reason to give the anesthesia team a more precise picture, never a reason to leave it out.
"There is no dose small enough to be worth not mentioning. The conversation costs nothing and it is the entire intervention."
Frequently asked questions
Do I need to stop a GLP-1 medication before surgery?
That decision belongs to the anesthesiologist and the proceduralist, and the guidance behind it changed meaningfully between 2023 and 2024. The 2023 American Society of Anesthesiologists consensus statement recommended holding weekly GLP-1 receptor agonists for one week and daily formulations on the day of the procedure. The 2024 multisociety guidance, developed jointly by anesthesiology, gastroenterology, and bariatric surgery groups, moved to a risk-stratified approach in which most patients continue the medication while following a 24-hour clear liquid diet. What has not changed is the obligation to tell the anesthesia team you are taking one, well before the day of the procedure.
Why does a GLP-1 medication matter for anesthesia at all?
GLP-1 receptor agonists slow gastric emptying, which is part of how they reduce appetite. Standard preoperative fasting rules assume a stomach that empties on a predictable schedule, roughly two hours for clear liquids and six to eight hours for solid food. If emptying is slowed, food can remain in the stomach past the point where the fasting rule says it should be gone. Anesthesia suppresses the reflexes that normally keep stomach contents out of the airway, so residual gastric content is the specific concern rather than the medication itself.
How often is food actually still in the stomach?
Endoscopy studies give the clearest picture because the operator can see directly. Retained gastric content after an adequate fast has been reported in roughly a quarter of GLP-1 users compared with a low single-digit percentage of matched non-users, with published odds ratios commonly falling in the range of four to six. Those figures come largely from patients on standard therapeutic doses. The rate rises sharply among people reporting nausea, vomiting, or early fullness, and falls among those on stable low doses without symptoms.
Does a one-week hold clear the medication from the body?
No, and this is the most widely misunderstood part of the older guidance. Semaglutide has a half-life of about one week, so stopping seven days before a procedure leaves roughly half the drug still circulating. Tirzepatide, with a half-life closer to five days, falls to around a third over the same interval. A true washout to negligible levels would take four to five half-lives, meaning a month or more. The one-week hold was never a pharmacological clearance, and part of the rationale for the newer risk-stratified guidance is that a rule which does not empty the stomach should not be treated as though it does.
Does dose size change the risk?
Gastric emptying delay from GLP-1 receptor agonists is dose-dependent, and pharmacology studies measuring emptying across the semaglutide dose range show a clear gradient from the starting dose to the maximum. A protocol that stays at a fraction of a therapeutic dose produces less slowing than one titrated to 2.4 mg. That is a mechanistic argument rather than a safety clearance, because no trial has compared microdose and full-dose protocols for residual gastric content or aspiration outcomes, and no dose has been established as a level at which the fasting question stops applying.
Does the effect on gastric emptying fade over time?
The slowing of gastric emptying attenuates substantially with continued exposure, a pattern documented across the GLP-1 class. Crossover studies of semaglutide have found the delay markedly reduced by around week twelve compared with the first weeks of treatment, while appetite effects persist. This is why the escalation phase, not month eight, is the period most associated with residual gastric content, and why someone stable on the same dose for a year is in a different situation than someone who moved up a step last week.
What is a clear liquid diet in this context?
A clear liquid diet in preoperative preparation means liquids you can see through, such as water, clear broth, apple juice without pulp, plain tea, and black coffee without milk. It excludes anything with solid particles, milk, cream, or protein shakes. The 2024 multisociety guidance places a 24-hour clear liquid diet at the center of preparation for GLP-1 users because liquids empty from the stomach through a different mechanism than solids, and the delay caused by these medications affects solids far more. The instruction still has to come from the procedural team, since some procedures have their own preparation requirements that override general advice.
What should I actually tell my care team?
Name the specific medication, the dose, the date of the most recent injection, how long you have been at the current dose, and whether you are in an escalation phase. Add whether you have had nausea, vomiting, bloating, or a sense of food sitting after meals in the past few weeks, and mention any prior gastroparesis or long-standing diabetes. Do this at the time the procedure is booked rather than on the morning of, because a one-week interval cannot be created on the day of surgery. This applies equally to compounded and prescribed sources, and to any protocol taken off label.
Clinical references
- Joshi GP, Abdelmalak BB, Weigel WA, et al. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists. American Society of Anesthesiologists. 2023.
- Kindel TL, Wang AY, Wadhwa A, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clinical Gastroenterology and Hepatology and companion society publications. 2024.
- Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration. Anesthesiology. 2017;126(3):376-393.
- Silveira SQ, do Nascimento LA, Cavalcanti Moreira LM, et al. Relationship between perioperative semaglutide use and residual gastric content. Journal of Clinical Anesthesia. 2023;87:111091.
- Sherwin M, Hamburger J, Katz D, DeMaria S. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound. Canadian Journal of Anesthesia. 2023;70(8):1300-1306.
- Hiramoto B, Flanagan R, Muftah M, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis. American Journal of Gastroenterology. 2024;119(6):1126-1140.
- Jensen L, Hjerpsted JB, Hompesch M, et al. Effect of semaglutide on gastric emptying. Diabetes, Obesity and Metabolism and related pharmacokinetic reporting. 2018-2021.
- Perlas A, Van de Putte P, Van Houwe P, Chan VW. Gastric sonography in the fasted surgical patient: a novel scoring system. Anesthesia and Analgesia. 2013;116(2):357-363.
- Ozempic and Wegovy (semaglutide) injection, prescribing information, clinical pharmacology section. Novo Nordisk.
- Mounjaro and Zepbound (tirzepatide) injection, prescribing information, clinical pharmacology section. Eli Lilly and Company.
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice, not perioperative instruction, and not a substitute for the guidance of the anesthesiologist, surgeon, or proceduralist responsible for your care. Preoperative medication and fasting decisions must be made by that team, who can assess your history, your medications, and the specific procedure. GLP-1 microdosing is an off label approach and individual responses vary. Nothing here should be read as a claim that any dose or protocol is safe to continue before a procedure, or that a smaller dose removes the need to disclose it. Do not start, stop, hold, or adjust any medication on the basis of this article. Always tell your care team about every GLP-1 medication you are taking, including compounded products, at the time a procedure is scheduled.